Last reviewed · How we verify
Institut de cancérologie Strasbourg Europe — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
3 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Administration of L-TC | Administration of L-TC | phase 3 | Oncology | |||
| Thero2-01S22 | Thero2-01S22 | phase 3 | ||||
| Paclitaxel + Trastuzumab | Paclitaxel + Trastuzumab | phase 3 | Taxane + monoclonal antibody | Microtubules + HER2/neu receptor | Oncology |
Therapeutic area mix
- Oncology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Institut de cancérologie Strasbourg Europe:
- Institut de cancérologie Strasbourg Europe pipeline updates — RSS
- Institut de cancérologie Strasbourg Europe pipeline updates — Atom
- Institut de cancérologie Strasbourg Europe pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Institut de cancérologie Strasbourg Europe — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-de-canc-rologie-strasbourg-europe. Accessed 2026-05-18.